Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Completes $75M Acquisition of MilliporeSigma's Flow Cytometry Portfolio

NEW YORK (GenomeWeb) – Luminex said today that it has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio for $75 million in combined purchases of stock, assets, and inventory.

The newly acquired flow cytometry portfolio includes Amnis imaging flow cytometry products for cell-based analysis and the Guava portfolio of products, which leverage microcapillary technology and are also used for cell-based analysis.

Homi Shamir, president and CEO of Luminex, said in a statement that the acquired Amnis and Guava products complement Luminex's range of flow-based products. "This acquisition enables us to enhance our existing offering of flow-based detection systems, while simultaneously expanding our direct interactions with researchers conducting cellular analysis," he said.

With the acquisition, Luminex has expanded its installed base of flow cytometry systems to more than 5,000.

The firm said it anticipates that the acquisition will contribute $40 million to $50 million to its revenue in 2019. It said previously that the total acquisition fee consists of about $69.9 million to be paid under a stock and asset purchase agreement and about $5.1 million in committed inventory purchases.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.